Derms on Drugs

This week on Derms on Drugs, the gang goes deep into vulvar dermatology with double-boarded derm/OB-GYN expert Dr. Kelly Tyler. From lichen sclerosus and recurrent candidiasis to estrogen, lasers, PRP, and the wildly overmarketed “Mona Lisa” treatments, they they break down what helps, what doesn’t, and what’s probably paying for someone’s boat. Equal parts practical pearls and inappropriate laughter — exactly how medical education should be.

This week’s Derms on Drugs is a 6-pack that covers a little bit of everything and somehow lands on: just do what you want. From a randomized trial showing eczema doesn’t care how often you shower to wild dupilumab data—plus a heating pad “treatment” that might actually work and a new JAK/TYK2 raising eyebrows—this one is equal parts useful, questionable, and predictably unpredictable.

Feeling a little worn down by Friday? A bit… degenerated, perhaps? This week’s Derms on Drugs goes off the beaten path and into the world of regenerative dermatology, where the line between legit science and “sounds like a scam” gets… blurry. With guest Dr. Amanda Hill, the team tackles hormones, skin aging, and whether we’re actually regenerating tissue—or just getting better at marketing it. From estrogen myths (and what we got very wrong) to PRP, exosomes, and the truth about “bioidentical” everything, this one separates hype from what might actually matter—and calls out a lot of nonsense along the way.

This week’s Derms on Drugs 6-pack moves past theory and into real decisions—what actually helps you pick the rightdrug for the patient in front of you. From gene expression profiling that predicts JAK vs Th2 response to the growing concern around dupilumab and CTCL, and more, this episode separates signal from noise—and gives you a few things you won’t forget (looking at you, abscopal effect).

Couldn’t make it to Denver for AAD—or made it to Part 1 but still hungry for the rest? Derms on Drugs is back with Part 2, finishing the job with more of the hottest late-breaking data in dermatology. Join Drs. Zirwas, Ferris, and Patton as they dive into the remaining abstracts, breaking down what actually matters (and what doesn’t) with the same unfiltered, practical take you expect from the DoD crew.

Couldn't make it to Denver for the AAD conference?  Made it to Denver but maybe had one too many Old Fashions to make it to the late breaking abstract presentations?  DoD may have had too many Old Fashions (it was really only Dr. Zirwas), but we still made it to the session with all the hottest data in the world of dermatology.  Join Drs. Zirwas, Ferris, and Patton for the first episode of this pair that'll keep you ahead of the curve.  

Some studies make you rethink everything. Others… not so much. This week, it’s a classic Derms on Drugs 6-pack that sorts through what’s actually useful, what’s overhyped, and what might quietly change how you practice. Can Castle testing spare sentinel node biopsies—or not yet? And why U.S. derms (and Patton) disagree with Europe on BP guidance. Plus more!

The Derms on Drugs get schooled on Hidradenitis Suppurativa by Dr. Chris Sayed from the University of North Carolina.  This will be one of the most practically useful sessions you've ever heard as we go way beyond the basics - we go way beyond basics like the biologics that don't work all that well.We'll get into a bunch of questions you probably haven't hear discussed with HS before:- What's the window of opportunity in HS and how do you keep it open?- Is there any such thing as mild HS?- What antibiotics actually work for HS and how do you use them?- Do ancillary treatments like spironolactone, metronidazole and oral roflumilast actually move the needle in a meaningful way?- If you're going to learn one surgical technique to really help your HS patients which procedure should you pick and how should you learn it?- What will be the likely role of JAK Inhibitors in HS?- Is it actually possible to get patients with long term, scarring severe HS better?

Melanoma, extramammary paget's and a prostate cancer drug walk into a bar... well, it may sound like a joke, but this week's episode is no laughing matter!  Join the Derms on Drugs as we get into some deep topics:New data on Castle Gene Expression Profiling for thin melanomas - does it finally answer the age old question question:  To send or not to send?Did you know that as we get older, our lymphatics get leaky and it is actually pretty important when it comes to melanoma?Extramammary Paget's Disease (EMPD) is a bad actor - when you see it, what should you do about it? Wide local excision vs Mohs vs Mohs plus radiation?You know Dr. Patton's a nerd.  But this week is off the charts.  You'll learn more about pathological staining of EMPD that you ever wanted.Bicaludamide?  Better than spironolactone for female pattern hair loss?  What do you need to know to start prescribing it?Pruritus in renal failure patients is the WORST, turns out that medications can be a big driving factor and stopping them might be all you need to do.

Matt, Laura, and Tim are joined by Dr. Lauren Graham (UAB) for a deep dive into cutaneous connective tissue disease. They cover the latest in lupus treatment — including the game-changing anifrolumab and its emerging sub-Q formulation — plus dermatomyositis workup, malignancy screening, the buzz around brepocitinib, and whether roflumilast deserves a spot as first-line therapy. 

The Derms on Drugs are back it, answering the burning questions you didn't know you had.  This week's hot topics:Aviclear laser new data just dropped. Realistic alternative to Accutane or just another device that sits in the corner and gathers dust?Does mycophenolate actually do anything in pemphigus?More data about Dupixent, CTCL and cancer.  Does it help, hurt or it's a wash?What happens if you get scabies while you're on Dupixent?  Turns out Zirwas has been wrong about this for years.Who is at risk for hyperkalemia on spironolactone and is it bad enough that we should care?Our goal in early hidradenitis is to prevent progression to scarring - what factors that predict who is likely to progress and what can prevent it?There's a new side effect to worry about with JAK inhibitors and we promise you won't forget about it.Finally, what do you say when a patient says "What would you do?"

Big news on TB Tests for psoriasis patients on biologics! New official recommendations say not necessary for IL-17s and IL-23s.  Literally zero cases.  Ever.  Think nicotinamide prevents skin cancer?  Think again.  Not saying it doesn't, but turns out data isn't really there and the jury is still out. How safe are topical steroids?  Depends.  Depends what else you're taking, especially NSAIDS - turns out it may increase your risk of an upper GI pretty substantially.If somebody doesn't respond adequately to Dupixent, what happens if you switch them to Rinvoq?  Abbvie kind of answered the question, but not really.Just how well does Rhapsido work in CSU?  And does it actually cause bleeding? No, no it does not.  But we're understanding more and more about why it causes petechiae.  Are PDE4 inhibitors like apremilast and roflumilast effective for bullous pemphigoid?  Maybe.  Do Sotyktu (and the new TYK2 inhibitors coming soon) work for atopic dermatitis?  We got our first data and it looks like they are pretty great. 

The Derms on Drugs are back at it, answering the burning derm questions you didn't even know you had.  Join us this week as we dive into more "outside the box" therapies that you can use next week in the office.-Is low dose naltrexone a lifeline in difficult dermatoses or a false hope?-There's been some chatter around metformin for hidradenitis suppurativa.  Is it hype or hope?-Diet and chronic spontaneous urticaria - Patients always ask and while we know it isn't food allergy, new data says that diet does play a role and gives us a simple intervention that's worth trying.-Everybody hates warts and we're always looking for pain free treatment options - could a heating pad and hydrogen peroxide be the answer?-Can we knock out psoriasis long term with a few months of high dose IL-23 inhibition?-We love tranexamic acid for melasma, but does oral or topical work better?-Once a vitiligo patient gets better, can you stop the Opzelura?-Fact or Fiction:  Compared to PLEVA, PLC lasts longer and happens in adults more than kids?

The Derms on Drugs are joined by Dr. Peter Lio to take a dive into the "root causes" of atopic dermatitis and what we can do to address them.  Maybe you've heard about the "NICE" Axis - the Neuro-Immuno-Cutaneo-Endocrine Axis and thought you were on the cutting edge.  Well, you're not.  The new and updated model is the "SINGE" Network - the Skin-Immuno-Neuro-Gastro-Endocrine Network.  Join us this week to get the answers to more of the questions you didn't know you should have!New data confirms again that elimination diets don't help with atopic dermatitis and data shows that avoiding foods makes you more likely so how do you talk to patients who are convinced food allergy is driving their atopic dermatitis?Should you be recommending probiotics to you atopic dermatitis patients (and which one)?How (and why) do probiotics work for atopic dermatitis?What does a lion in your basement have to do with atopic dermatitis?How do you handle patients who say that all moisturizers sting when you put them on?How do you deal with people in whom Staph aureus is playing a major role in their atopic dermatitis?What's coming for atopic dermatitis in 2026?

This week's episode will help you not get sued, talk to psoriasis patients about diet, manage transplant patients with skin cancer and more.  Join us again this week to get the answers to burning dermatology questions you didn't know you had.   Can the Mediterranean diet help with psoriasis?  And why do people get 'gluten sensitivity' from US wheat but not Mediterranean wheat?When do you recommend changing immunosuppression in transplant patients with skin cancer?Are people with atopic dermatitis more or less likely to have contact derm than other people?Hailey Hailey is an awful disease that's hard to treat - can dupilumab help?  What other 'off the beaten path' therapies are there?Cosibelimab is the new kid on the block for bad squamous cell carcinoma - is it any better than existing treatments?When do you need to be worried about underlying malignancy in dermatomyositis patients?Oral minoxidil causes hairy arms in men.  But do they care?You know Bactrim can cause SJS and TEN, but do you know about the other life threatening side effect that specifically affects young healthy people with acne?

The Derms on Drugs bring in a heavy hitter straight out of silicon valley to talk AI and the future of dermatology.  Dr. Faranak Kamangar is a Board Certified Dermatologist who founded, built and continues to improve DermGPT - a derm specific LLM that just outperformed ChatGPT in a head-to-head contest judged by dermatologists!  As usual, we'll answer the questions you didn't know you had (well, maybe you knew you had some of these):Is AI going to make our lives easier or is it going to replace us?How good is AI at answering patient questions?Will patients accept "AI Providers"?How can you start levering AI now to make your life better?What AI tools are out there to start using right now?Are AI scribes all that great?

The Derms on Drugs give the definitive answer to the age old question:  What came first, the chicken or the egg?  You'll have to listen to find out.  What's a Mazotti Reaction and why do you care?How do JAK inhibitors compare to dupilumab for treating prurigo nodularis?What's a cheap, easy, safe, effective treatment for palmoplantar pustulosis?Can a steroid nasal spray help for Chronic Spontaneous Urticaria?Do biologics reduce infection risk in AD more than JAK Inhibitors and why?How does superficial radiation therapy compare to Mohs for skin cancer?Dermal hyperpigmentation is impossible to treat - can isotretinoin help?Cheilitis drives derms and patients nuts - what's the new, cheap, easy way to help?

Get ready for a no-nonsense tour-de-force of practical application in the latest derm literature. Pipeline drugs, new approvals, brand names, generics—and HS data you’re better off ignoring (we’ll tell you why). In this episode:·       Leqselvi: the newest JAK for alopecia areata—actually different, or more of the same?·       HS & spondyloarthritis: are you screening… should you be?·       JAKs and the heart: are all cardiovascular risks created equal?·       “2/3 HS remission” headlines: why this data shouldn’t change your practice·       Tirbanibulin + cryo for AKs: combo win or marketing math?·       Hydrochlorothiazide & skin cancer: do you really need that conversation?·       Oral minoxidil + Olumiant: synergy or wishful thinking in AA?·       OX40/OX40L blockers: exciting pathway—new hope or new hype? Fast. Practical. Slightly skeptical (for good reason).If you prescribe, counsel, or roll your eyes at bad data—this one’s for you.

Listening this week could save your life (well, at least your kidneys).  Find out what common ingredient in keratin treatments you (and your friends, family and patients) NEED to avoid.  But there's a lot more than that packed into this week's episode.  As always, the Derms on Drugs bring the goods on the latest questions that the literature is answering:-Is isotretinoin making kids short?  -Is Dupixent making them tall?  -What is "transcutaneous auricular vagus nerve stimulation" and which common but difficult derm disease does it help with?  -What OTC supplement makes NBUVB work better for vitiligo?  -What oral drug can you add to isotretinoin to make it work even better?  -Does oral tranexamic acid increase the risk of blood clots when used in dermatology?-How well does Opzelura work for hidradenitis suppurativa?-Do Humira biosimilars work as well as Humira in hidradenitis suppurativa?-What common statistical technique used by pharma is total BS?-Which ingredient in 'keratin treatments" is causing kidney failure and kidney stones? 

Admit it—bad hair days are the worst. Now imagine every day is one. Alopecia’s psychological impact is way deeper (and more surprising) than most people think. This week, the Derms on Drugs sit down with Harvard’s Dr. Maryanne Makredes Senna to unpack the mental side of AA—and then dive into what to do when a JAK inhibitor just… doesn’t JAK. As always, we’re answering the questions you didn’t even know you had.Here’s what we’re tackling:What hits harder on anxiety and depression—scarring or non-scarring alopecia?How tightly does AA severity track with psychological burden?How should you approach the mental health effects of AA?(Yes, you should ask. No, you shouldn’t be the one treating—here’s how to bridge patients to the right therapists.)And what do you do when a JAK Inhibitor isn’t giving you the results you hoped for?

This week, the Derms on Drugs are back with another literature speed-run—think 3D chess meets derm nerd nirvana. We’re answering questions you didn’t even know you had (and a few you wish you didn’t).Here’s what we’re tackling:Do herbal supplements turn up dermatomyositis?Can biologics cut down on blood clots in HS?Wait… does Claritin supercharge isotretinoin?Is Sotyktu stirring up rosacea?How good is the new oral IL-23 inhibitor icotrokinra for psoriasis?Any fresh weapons against demodex?Anything new for those stubborn pemphigus oral lesions?What to do when your patient is resistant to multiple botulinum toxins?And—holy grail alert—can we actually prevent chemo-induced alopecia in breast cancer?

The Derms on Drugs are joined by Dr. Crystal Aguh from Johns Hopkins for an AMAZING discussion on central centrifugal scarring alopecia.  From uber practical, cheap, safe, effective treatment approaches to deep science on what is happening in this disease, listen this week and you'll be an expert - how to talk to these patients, the baseline treatments everybody should be on, when to get more aggressive, when to step therapy back - the whole enchilada.  We even throw in a little frontal fibrosing alopecia.  Quite honestly one of the best episodes we've ever done.  The Derms on Drugs learned new approaches to this disease and we promise, you will too!

Join us this week as the Derms on Drugs crew discusses the latest in the Dermatology literature.  Topics for this episode include: - Cutaneous vasculitis of the skin (it’s a Chapel Hill thing)- Ozempic face, butt, and body- TAC injections for AA – what concentration do you use?- Does the MERLIN study deserve its magical name?- Are systemic JAK inhibitors the answer for vitiligo?- And everyone’s favorite – Demodex mites!

You don't see a lot of kids with psoriasis, but when you do it can be a big challenge, especially if it's bad and they need a systemic.  The Derms on Drugs are coming to the rescue!  We'll have a special guest - Dr. Doug Kress (who was heavily involved in training all three of the Derms on Drugs) who has enormous experience treating pediatric psoriasis.  We'll get into all the stuff you really need to know:-What systemic drugs are approved for psoriasis under the age of 18?-What does the data say about which ones work the best?-How good is Tremfya, the first IL-23 inhibitor approved in kids, and where will it fit?-How is psoriasis in kids different from psoriasis in adults?-What are the roles of the different topicals approved for psoriasis in kids?-How do we think about therapy selection differently in kids vs adults?-Do kids get psoriatic arthritis?-What about shots vs pills in kids?-How do you talk to parents about the different biologics for kids?-How do you handle vaccines in kids who are psoriasis biologics?-Do you ever use methotrexate in kids?

Brought to you by Scholars In Medicine  The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like:  -Do tattoos protect people against melanoma? -What cheap, easy topical works great for fissures in hand eczema? -Is Dupixent safe in pregnancy? -Are tinted sunscreens actually better than regular mineral sunscreens for melasma? -If an alopecia areata patient has failed two or three JAKs, is it worth trying another one? -What does the early data show for systemic JAK efficacy in vitiligo? -Is there anything better than triamcinolone to inject keloids with? -Does some crazy drug Patton found an article about work for hemodialysis associated itch?  So, join us for another episode that'll make you better at what you do while you're having fun listening! 

Join the Derms on Drugs and Dr. Shanthi Narla as we dive into the world of obesity, GLP-1s and dermatology.  Whatever you think about all of these topics, we promise that your patients are hearing about them, reading about them and will be asking about them.  Specifically, we'll get into the latest data about how GLP-1s affect diseases like psoriasis, hidradenitis suppurativa and atopic dermatitis and we'll even touch on if dermatologists should be prescribing GLP-1s.  So, while there aren't any definite answers out there yet, tune in this week and you'll be ready when these hot topics come up!

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Join the Derms on Drugs as we slice and dice the latest dermatology literature.  We've got stuff that will change what you do next week, answers for uncommon but challenging diseases and the latest updates on the pharma pipeline.  We'll answer burning questions, like:-When is the best time to start niacinamide for skin cancer prevention?-Which drugs work the best for the itch of atopic dermatitis and prurigo nodularis?-Is minoxidil 5 mg actually better than minoxidil 2.5 mg?-What can do when for PLEVA that's not responding to the usual treatments?-Is icotrokinra (the new oral IL-23 inhibitor) more effective than Sotyktu?-What can you do for patients with skin involvement of systemic mastocytosis?-Are there patients who really have both atopic dermatitis AND psoriasis?-Opzelura just got approved down to age 2 - how well does it work in that age range? 

Ever wonder if you can trust those network meta-analyses (NMAs) flooding dermatology journals? Join the Derms on Drugs and University of Toronto expert Dr. Aaron Drucker for a critical deep dive into NMAs—what they are, how they work, and whether dermatologists should rely on them for treatment decisions.NMAs promise head-to-head comparisons for drugs without having to do a head-to-head trial, especially in psoriasis, hidradenitis suppurativa, atopic dermatitis, and soon alopecia areata. But here's the catch: different NMAs on the same topic can give conflicting results about which treatments work best.In this episode, we tackle:-What network meta-analyses actually measure and how they're conducted-Why two NMAs can reach opposite conclusions about drug effectiveness-Red flags to watch for when evaluating NMA quality and reliability-Practical guidance for incorporating NMA findings into clinical practicePerfect for dermatology providers, researchers, and pharma professionals who want to critically evaluate the evidence behind treatment guidelines. Tune in for expert analysis that might surprise you about this increasingly common research methodology.Listen now to become a smarter consumer of dermatology research! And be sure to discover more at Scholars In Medicine!

Welcome back to Derms on Drugs! Today we’re cracking open a six-pack—not IPAs, but papers. We’ve got polyomavirus antibodies sneaking in as early markers for Merkel cell recurrence, collagen supplements promising to smooth wrinkles or just make your bank accounts smaller, and ruxolitinib cream stepping up for the disaster that is chronic hand eczema.But wait—there’s more! Isotretinoin is back, this time for seb derm instead of acne, actinic cheilitis gets the meta-analysis glow-up, lentigo maligna sees radiation face off against imiquimod, and atopic dermatitis therapies can shake up the skin microbiome, but which ones do it better?Six papers, one podcast, and probably at least three things you’ll be telling your colleagues about tomorrow. Let’s crack into it!

Join the Derms on Drugs and Dr. Marc Serota (who is triple boarded in dermatology, allergy and pediatrics) to find out the latest on how to think about the causes of chronic spontaneous urticaria - it can be autoimmune, it can literally be an "allergy to yourself" or it can be neither of the above.  Crucially, there are clinical clues to which one it is, and if you can figure out which one it is, it helps predict the response to therapy!So join us for a deep dive into CSU, and yes, there will be trivia at the end!Visit the ⁠Scholars In Medicine⁠ website for more.

Get ahead of the curve with Derms on Drugs as we break down the most exciting new dermatology research! This week features game-changing studies including an oral probiotic with stunning results for atopic dermatitis, JAK inhibitors for bullous pemphigoid, and IL-23 inhibitors tackling guttate psoriasis.Plus, we dive deep into:Dermoscopy advances for managing longitudinal melanonychiaIf failing an IL-13 inhibitor affects the chances of doing well on another IL-13 inhibitorNew data on IL-13 inhibitor induced conjunctivitisRed light PDT efficacy for superficial basal cell carcinomaEarly systemic PDE4 inhibition strategies in psoriasisFollicular event insights from tapinarof studiesPDE4 inhibition potential for vitiligo treatmentPerfect for dermatology providers who want cutting-edge clinical pearls they can apply immediately. Tune in for evidence-based insights, practical takeaways, and the signature Derms on Drugs commentary that keeps you engaged while staying current.See more at ScholarsInMedicine.com

Stay at the forefront of dermatology with the Derms on Drugs and their special guest Dr. Scott Drew! This episode is a rapid-fire roundup of the latest journal pearls-perfect for busy practitioners looking to keep up with the latest evidence in the literature.We cover:Can moisturizing infants prevent atopic dermatitis?New sunscreen ingredients headed for the US marketInsights from lichenoid eruptions linked to immune checkpoint inhibitorsWhat to do if oral JAKs fail in alopecia areataDoes CeraVe outperform other moisturizers?The real risk of cardiovascular and thromboembolic events with JAK inhibitorsWhy IL-13 inhibitors differ in likelihood of causing arthralgiasAdvances in autologous skin cell transplantation for vitiligoThe safety of patients self-injecting triamcinolone for acneNew findings on hypersensitivity reactions after sentinel lymph node biopsyCan patch testing help with burning mouth syndrome?A drug that reduces cardiovascular mortality in hidradenitis suppurativaNovel approaches for chronic erythema nodosum, frontal fibrosing alopecia, and cheilitis granulomatosisJoin us for concise, actionable updates and real-world pearls you can apply in clinic today. Whether you’re managing complex cases or keeping up with the literature, this is one episode you don’t want to miss.Listen now and stay ahead in dermatology!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling all kinds of medical diseases - whether we're talking about patients who can't access (or don't respond adequately) to our highly effective FDA approved drugs for psoriasis, atopic dermatitis, alopecia areata, hidradenitis or about patients with diseases that don't have an extremely effective FDA approved drug - things like lichen planus, granuloma annulare, dermatitis herpetiformis and many, many more.  This week, we talk through dapsone, roflumilast, and acitretin.In this episode, you’ll learn:Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.Tune in for clinical pearls and expert insights you can put to work in your practice!

The Derms on Drugs take on the latest, greatest and coolest stuff from the Derm literature.  Quite honestly, there was some stuff this week that just seems crazy and that you won't want to miss.  Join us as we discuss questions like:-Do tattoos protect people against melanoma?-What cheap, easy topical works great for fissures in hand eczema?-Is Dupixent safe in pregnancy?-Are tinted sunscreens actually better than regular mineral sunscreens for melasma?-If an alopecia areata patient has failed two or three JAKs, is it worth trying another one?-What does the early data show for systemic JAK efficacy in vitiligo?-Is there anything better than triamcinolone to inject keloids with?-Does some crazy drug Patton found an article about work for hemodialysis associated itch?So, join us for another episode that'll make you better at what you do while you're having fun listening!

Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.In this episode, you’ll learn:--When and why to reach for these time-tested therapies in real-world practice--How to monitor labs and counsel patients for safety and success--Tips for discussing off-label treatments and navigating complex casesPerfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.Tune in for clinical pearls and expert insights you can put to work in your practice!Article titles:1.  Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial2.  Lower Oncogenic Risk with Dermatologic Use of Mycophenolate Mofetil Compared to Transplant Prophylaxis: A Retrospective Study3.  Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis

Today on Derms on Drugs we’ve got the fabulous Dr. Heather Woolery-Lloyd with us, and yes—we’re talking sunscreens. Don’t roll your eyes, because we’re going way past “SPF 30 or 50?” into the good stuff: how these lotions and potions actually work, which myths need to finally get buried, and why tinted sunscreens aren’t just makeup but legit medicine for skin of color.We’ll also dish on the brand-new Aussie rules for UV protection and spill which brands actually look good on darker skin without turning you into a ghost.And because no episode is complete without it, we’ll detour into lifestyle hacks, chat a little nutrition, and finish with our usual trivia shenanigans.So, grab your SPF (tinted or not, we don’t judge), and let’s dive in"

Welcome back to another episode of Derms on Drugs—where we prescribe only the highest yield practical pearls (and zero prior authorizations are ever required). If dermatology conferences make you yawn but a six-pack of journal articles gets your heart racing, you’re definitely in the right clinic!What’s on Tap in Our 6 Pack Episode?Today, we’re serving up a refreshing six-pack—no ice needed, but plenty of cool research to keep you hydrated with knowledge:New Therapy for Recessive Dystrophic Epidermolysis Bullosa: We’re walking through the latest clinical trial that could be a real gamechanger.Homemade vs. Commercial Sunscreens: Should your patients blend SPF cocktails in the kitchen, or is that a recipe for disaster?Immunosuppressives and Patch Testing: Just how “immunosuppressed” can your patients be and still get valid patch testing results? We’ve got the hottest updates from the experts—no immuno-anxiety required.HPV Vaccine vs. Actinic Keratoses: A blockbuster therapy for warty issues? This clinical trial investigates the HPV vax as a new weapon in the fight against actinic keratoses.Hailey-Hailey Disease Treatment Algorithms: Confused by this rare disease? We’re breaking down shiny new algorithms so you can manage it like a pro.JAK Inhibitor Discontinuation and Heart Risks: Why do patients sometimes trade clear skin for cardiac drama after stopping a JAK inhibitor? The science just got spicier, and we’ve got the scoop.So scrub in, sit back, and let us put the “fun” in fundamentals as we break down the latest, greatest (and occasionally weirdest) in the world of clinical dermatology. Let’s pop open that six-pack and get started.And for links to all of the articles we discussed in this episode, visit ScholarsInMedicine.com

Welcome to another episode of Derms on Drugs, where we peel back the layers on the latest in dermatology therapeutics. Today, we’re thrilled to have Dr. Donna Culton join us for a deep dive into the world of bullous pemphigoidIn this episode we:Review three of the hottest papers on bullous pemphigoid, dissecting the latest evidence with our signature blend of rigor and irreverence.Break down the recent FDA approval of dupilumab for bullous pemphigoid—a new kid on the blister block!Unpack the pivotal dupilumab study results, then pit them against real-world evidence. Does the hype hold up outside the ivory tower?Debate how we’ll actually integrate dupilumab into our clinical arsenal. Is this a game-changer or just another tool in the kit?Explore the real impact on patient care: Will this approval mean fewer steroids, better outcomes, or simply more options for those tough-to-treat cases?Refresher course in bullous pemphigoid - diagnosis and practical treatment pearlsSo, whether you’re a seasoned derm or just here for the laughs, tune in as we blister through the data and get under the skin of bullous pemphigoid’s newest treatment frontier.For Links to articles please go to ScholarsinMedicine.com1. Bullous pemphigoid: A practical approach to diagnosis and management in the modern era2. Effectiveness of Dupilumab and Omalizumab in Bullous Pemphigoid: A Nationwide Retrospective Cohort Study3. Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT

Welcome to the first-ever Derms on Drugs Debate! Our brave hosts tackle three of the hottest—and most controversial—questions in the field:Castle Gene Expression Profile in Melanoma: Should dermatologists use it for almost every melanoma, just those “close to 1 mm,” or leave it to the oncologists?Zoryve, VTAMA and Opzelura: All great drugs, but if you could only keep one, which would it be? Our hosts go head-to-head to defend their picks.The Next Game Changer in Dermatology: Will it be AI-powered skin cancer diagnosis, BTK inhibitors, or the first generic oral JAK? Hear our predictions and the cases for each.Whether you’re a dermatology provider, researcher, or pharma professional, you’ll get expert insights, practical takeaways, and plenty of lively debate—Derms on Drugs style.Tune in for clinical pearls, bold opinions, and a fresh look at the future of dermatology. Don’t miss out—hit play and join the debate!

Ready to level up your medical dermatology game? This week, Derms on Drugs tackles the toughest questions and latest controversies in serious derm—served with our signature practical, no-nonsense style with a big dose of humor.We break down the newest literature and answer:Does immunotherapy really help with high-risk squamous cell carcinoma?Are pemphigus patients getting more rituximab than they need?Why don’t JAK inhibitors increase cardiovascular risk in atopic dermatitis?Is the Mind.Px test actually helpful for picking a psoriasis biologic?What does drug level monitoring tell us about adalimumab in hidradenitis suppurativa?Which treatment factors predict scabies cure?Perfect for dermatology providers and industry pros who want clinical pearls, evidence-based answers, and a few laughs along the way. Tune in for the most fun you’ll have while getting smarter about serious medical derm!Hit play and stay on the cutting edge of medical dermatology!1.  Adjuvant Cemiplimab or Placebo in HighRisk Cutaneous Squamous-Cell Carcinoma2.  Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial3.  Understanding Cardiovascular Events With JAK Inhibitors: Tofacitinib Reduces Synovial and Vascular Inflammation but not the Prothrombotic Effects of Inflammatory Cytokines on Endothelium4.  Is Upadacitinib Cardioprotective in Chronic Inflammatory Diseases? A Review of Major Adverse Cardiovascular Events and Venous Thromboembolism in Atopic Dermatitis5.  Clinical Utility Findings of a Transcriptomic Psoriasis Biologic Test Demonstrate Altered Physician Prescribing Behavior and Improved Patient Outcomes6.  Therapeutic Drug Monitoring in Hidradenitis Suppurativa Patients With Suboptimal Treatment Response to Adalimumab7.  Scabies Management Outcomes: Identification of Risk Factors for Treatment Success or Failure

Chronic Spontaneous Urticaria (CSU) is back in the dermatology spotlight—and for good reason. Join the Derms on Drugs as we break down the latest clinical trial data on Dupixent (dupilumab) and the buzzworthy new oral BTK inhibitor, remibrutinib, both showing real promise for CSU patients who’ve hit a wall with antihistamines.We’re joined by CSU expert Dr. Jason Hawkes to discuss:-How Dupixent is changing the game for CSU and why dermatologists are leading the charge-What makes remibrutinib “fast, sexy, and safe”—plus what the new Phase III data means for your patients-How we explain to CSU patients that they don’t need allergy testing!-Clinical pearls for work-up, navigating treatment guidelines, safety, and accessPerfect for derm providers who want the latest on CSU pathophysiology, emerging therapies, and patient communication. Tune in for actionable insights, expert commentary, and a dose of Derms on Drugs humor—because managing hives shouldn’t be a headache.Hit play and stay ahead on the cutting edge of CSU care!1.  Autoimmune Thyroid Diseases in Chronic Spontaneous Urticaria: The Role of Hormones, Anti-Thyroid Antibodies, and Ultrasound2.  Remibrutinib in Chronic Spontaneous Urticaria3.  Dupilumab in patients with chronic spontaneous urticaria (LIBERTY-CSU CUPID): Two randomized, double-blind, placebo-controlled, phase 3 trials

Ready to stay ahead in dermatology? Join the Derms on Drugs for a fast-paced, practical dive into the hottest new research and trends shaping our specialty.This week, we break down:Surprising long-term data comparing Dupixent and Rinvoq for atopic dermatitisThe future of autoimmune disease treatment: genetically modified T cellsWhat policies people actually support (and will pay for) to reduce skin cancer ratesJAK inhibitors for mucosal pemphigoid—what’s new, what works, and what to watch forThe latest on rising contact allergens: which ones are on the move and whyPacked with clinical pearls, practical tips, and a dash of humor, this episode is your shortcut to what’s new, what’s changing, and what you can use in practice right now.Don’t miss out—hit play for your weekly dose of dermatology insights!For links to all articles visit ScholarsinMedicine.com1.  Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study2.  Janus Kinase Inhibitors in the Treatment of Refractory Cicatrizing Conjunctivitis in Pemphigoid3.  Long-Term Real-World Effectiveness of Dupilumab vs. Upadacitinib in early Treatment Responders with Atopic Dermatitis: Results from Central European Health Fund Registry4.  Mid-term effectiveness, safety, and potential predictors of response of upadacitinib in patients with moderate-to-severe atopic dermatitis: a multicenter observational retrospective study5.  Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents6.  Public preferences for skin cancer prevention policies: a discrete choice experiment in three European countries7. North American Contact Dermatitis Group Patch Test Results: 2021–2022

Ever feel overwhelmed by the flood of alopecia treatments and supplements?Join the Derms on Drugs as we cut through the noise with Dr. Michelle Tarbox, diving deep into the practical side of managing alopecia for dermatology providers.In this episode, we tackle:Which labs to order for telogen effluviumWhich hair loss supplements are actually worth recommendingThe truth about red light helmetsHow and when to use prescription therapies for hair lossCan shampoo really help with alopecia?Tune in for expert insights, practical tips, and a healthy dose of humor—perfect for medical providers who want to stay ahead in dermatology without getting lost in the latest hype.Listen now for all the answers—and maybe a few laughs!

Hair loss is common and devastating, both to the person losing their hair and the dermatology provider taking care of them.  Derms on Drugs to the rescue.  In part one of our deep dive into hair loss we cover three big topics:  1) What supplements for hair loss actually work?  You'll have heard (ad nauseum) about some of them, but we'll also bring you some ideas for cheap supplements you haven't heard of that actually work; 2) Do we really need to do lab work-ups in patients with telogen effluvium? and 3) What's the state of the art when it comes to diagnosing and managing folliculitis decalvans?  Join us for another episode with our trademark mix of evidence and banter!  #DermatologyPodcast #HairLoss #DermsOnDrugs #AlopeciaProduced by ScholarsinMedicine.comScholarsinMedicine.com⁠1.  Management of folliculitis decalvans: The EADV task force on hair diseases position statement2.  Retrospective Review of 2851 Female Patients With Telogen Effluvium: A Single-Center Experience3.  Impact of Laboratory Work Up and Supplementation on Alopecia Patients: A Single-Center Retrospective Chart Review4.  Evaluation of the Safety and Effectiveness of Nutritional Supplements for Treating Hair Loss A Systematic Review

Join Derms on Drugs for a must-hear episode packed with practical dermatology updates! Discover if Nutrafol Acne delivers, which skin care ingredients top cosmetic dermatologists swear by, and the latest breakthroughs for hand eczema. Plus, is Zoryve Foam a game-changer for psoriasis? And what’s the deal with PRAME staining for benign nevi? Get actionable insights to elevate your practice along with our usual banter. Derms on Drugs is produced by Scholars in Medicine.Resource links can be found at: Scholarsinmedicine.com1.  A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial for the Efficacy and Safety of a Novel Nutraceutical for Mild-to-Moderate Acne2.  Skincare Ingredients Recommended by Cosmetic Dermatologists: A Delphi Consensus Study3.  Efficacy and safety of topical delgocitinib cream versus oral alitretinoin capsules in adults with severe chronic hand eczema (DELTA FORCE): a 24-week, randomised, head-to-head, phase 3 trial4.  Oral roflumilast for the treatment of chronic hand eczema: a retrospective case series5.  Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body6.  Clinicopathologic Features of PRAME-Positive Common Melanocytic Nevi: A Case-Control Study

 Skyrocketing drug prices are hitting dermatology hard. Why are Americans paying more than other countries? Are Pharmacy Benefit Managers (PBMs) or pharmaceutical companies to blame? Join Derms on Drugs as our experts pull back the curtain on the broken system driving costs. Get insider insights, practical takeaways, and our trademark banter to navigate this mess as a clinician.Derms on Drugs is a production of Scholarsinmedicine.com1.  Use and Cost of First-Line Biologic Medications to Treat Plaque Psoriasis in the US2.  Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis3.  AI Description and Answers About How Drug Pricing WorksScholarsinmedicine.com

Join Derms on Drugs for a riveting dive into artificial intelligence and automated skin cancer detection. World-renowned expert Dr. Laura Ferris, with 20 years in the field, breaks down cutting-edge research and predicts the future of dermatology. Will AI "terminate" dermatologists or empower us to focus on complex cases and patient care? Expect fresh insights, practical takeaways, and lively banter that’ll make you a smarter clinician. Don’t miss this chance to stay ahead in the AI revolution!Derms on Drugs is produced by ⁠Scholars In MedicineFor Resources links visit: ⁠Scholars In Medicine⁠1.  Diagnostic performance of augmented intelligence with 2D and 3D total body photography and convolutional neural networks in a high-risk population for melanoma under real-world conditions: A new era of skin cancer screening?2.  3D Total-Body Photography in Patients at High Risk for Melanoma3.  Promises and Pitfalls of 3D Total-Body Photography for Melanoma Early Detection4.  Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance5.  Standard Dermatoscope Images vs an Autonomous Total Body Photography and Dermoscopic Imaging Device

Tune in to Derms on Drugs for a the most fun you can have while diving into the hottest dermatology topics! This week, we unpack cutting-edge insights from the latest literature to make you a sharper clinician. Explore adjuvant therapy for Stage 3A melanoma, the pitfalls of dermatomyositis misdiagnosis, and a surprising finding: is hydroxychloroquine outperforming NBUVB for vitiligo? Plus, discover new skin-gut-immune connections, tackle cancer immunotherapy-induced pemphigoid, and learn how to manage premenstrual rash flares in atopic dermatitis, contact dermatitis, and autoimmune progesterone dermatitis. Join our fun, banter-filled discussion to stay ahead in dermatology!In This Episode:Stage 3A Melanoma: Is adjuvant therapy worth it, and what’s the best option?Dermatomyositis: Consequences of misdiagnosis and delayed diagnosisVitiligo: Could hydroxychloroquine be a game-changer over NBUVB?Skin Inflammation: A key driver of food allergyPemphigoid: Insights into immunotherapy-induced casesPremenstrual Rashes: Managing flares in atopic1.  Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.2.  Patterns and Clinical Implications of Misdiagnosis in Dermatomyositis3.  Effectiveness, Tolerability and Safety of Topical Clobetasol with Oral Hydroxychloroquine versus Topical Clobetasol with NBUVB Phototherapy in Unstable Vitiligo: Investigator Blind, Randomized Controlled Trial4.  Skin damage signals mediate allergic sensitization to spatially unlinked antigen5.  Epitope Spreading in Immune Checkpoint Inhibitor–Associated Bullous Pemphigoid6.  The impact of the menstrual cycle on exacerbations of atopic dermatitis: a systematic review7.  Nickel contact allergy and menstrual cycle8.  Autoimmune progesterone dermatitis: Update and insightsDerms on Drugs is produced by ⁠⁠Scholars in Medicine.com

Should dermatologists offer Image Guided Superficial Radiation Therapy (IGSRT) in-office or refer radiation oncologists when radiation is appropriate? Join Derms on Drugs as we tackle this "burning" question with two expert radiation oncologists. While dermatologists are THE skin cancer experts, radiation therapy isn't our usual domain— so is IGSRT a game-changer for your practice or too far outside our realm? Explore clinical insights, practical considerations, and the latest evidence to guide your decision-making. Perfect for dermatologists, PAs, NPs, residents, medical students, and pharma professionals in dermatology seeking to stay ahead of the curve. Tune in to discover if IGSRT could light up your approach to patient care—or leave you glowing in the dark.#Dermatology #SkinCancer #IGSRT #RadiationTherapy #DermEducation1.  Updated results of 3,050 non-melanoma skin cancer (NMSC) lesions in 1725 patients treated with high resolution dermal ultrasoundguided superficial radiotherapy, a multiinstitutional study ScholarsInMedicine.com2.  The Role of Image-Guided Superficial Radiation Therapy in the Treatment of Nonmelanoma Skin Cancer3.  Effectiveness and Patient Experiences of Rhenium Skin Cancer Therapy for Nonmelanoma Skin Cancer: Interim Results from the EPIC-Skin Study